IRIS
CORREALE, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.207
NA - Nord America 2.069
AS - Asia 1.875
SA - Sud America 307
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 6.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.013
SG - Singapore 813
IE - Irlanda 643
CN - Cina 506
SE - Svezia 368
UA - Ucraina 275
BR - Brasile 260
RU - Federazione Russa 242
HK - Hong Kong 222
DE - Germania 178
IT - Italia 149
VN - Vietnam 123
FI - Finlandia 78
IN - India 71
AT - Austria 66
FR - Francia 52
GB - Regno Unito 49
CZ - Repubblica Ceca 43
TR - Turchia 34
CA - Canada 32
BD - Bangladesh 23
AR - Argentina 20
ZA - Sudafrica 19
IQ - Iraq 18
ES - Italia 15
MX - Messico 15
NL - Olanda 11
PL - Polonia 11
PK - Pakistan 10
TN - Tunisia 9
EC - Ecuador 8
LT - Lituania 7
BE - Belgio 6
JP - Giappone 6
KE - Kenya 6
VE - Venezuela 6
ID - Indonesia 5
MA - Marocco 5
PE - Perù 5
UZ - Uzbekistan 5
EG - Egitto 4
JO - Giordania 4
AZ - Azerbaigian 3
DZ - Algeria 3
HN - Honduras 3
IR - Iran 3
NP - Nepal 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BH - Bahrain 2
CL - Cile 2
CO - Colombia 2
CR - Costa Rica 2
EU - Europa 2
IL - Israele 2
JM - Giamaica 2
LB - Libano 2
MK - Macedonia 2
PH - Filippine 2
PS - Palestinian Territory 2
PY - Paraguay 2
SA - Arabia Saudita 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ML - Mali 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
TV - Tuvalu 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.515
Salva come PNG Salva come JPEG
Città #
Dublin 643
Singapore 355
Ashburn 333
Nyköping 233
Hong Kong 218
Chandler 187
Jacksonville 171
Beijing 169
Dallas 155
Santa Clara 107
Munich 103
Dearborn 72
New York 64
Nanjing 61
Princeton 61
Vienna 59
Los Angeles 54
Wilmington 45
Moscow 44
Helsinki 40
The Dalles 40
Ho Chi Minh City 38
Seattle 31
Boardman 30
Hanoi 30
Brno 28
Turku 25
Falkenstein 22
Nanchang 22
Pune 22
London 19
Frankfurt am Main 17
San Mateo 17
Guangzhou 16
Rome 16
Olomouc 15
São Paulo 15
Tianjin 15
Des Moines 14
Brooklyn 13
Johannesburg 13
San Francisco 13
Assago 12
Atlanta 12
Düsseldorf 12
Nuremberg 12
Jiaxing 11
Shenyang 11
Shanghai 10
Toronto 10
Warsaw 10
Changsha 9
Foggia 9
Hangzhou 9
Montreal 9
Boston 8
Da Nang 8
Haiphong 8
Jinan 8
Renton 8
Washington 8
Chennai 7
Kunming 7
Lauterbourg 7
Lund 7
Palermo 7
Stevenage 7
Tunis 7
Woodbridge 7
Ann Arbor 6
Brussels 6
Denver 6
Dhaka 6
Gesualdo 6
Hebei 6
Nairobi 6
Shenzhen 6
Acerra 5
Baghdad 5
Bari 5
Belo Horizonte 5
Chicago 5
Mexico City 5
Mumbai 5
Ningbo 5
Philadelphia 5
Phoenix 5
Portsmouth 5
Stockholm 5
Tashkent 5
Wuhan 5
Amman 4
Amsterdam 4
Changchun 4
Guayaquil 4
Karachi 4
Lanzhou 4
Messina 4
Ninh Bình 4
Norwalk 4
Totale 4.039
Salva come PNG Salva come JPEG
Nome #
Alcohol-induced cardiac disease 127
How to Assess Pulmonary Circulation and Right Heart Chambers in Systemic Sclerosis Patients? 123
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 119
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 118
Cardiopulmonary exercise test predicts right heart catheterization 113
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 111
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 105
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 104
Delirium in heart failure 104
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 103
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 101
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 100
Chronic thromboembolic pulmonary hypertension. 97
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 95
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 94
Biomarkers in cardiorenal syndrome 92
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 91
Liver disease and heart failure: Back and forth 91
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 90
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 89
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 89
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 88
Liver disease and heart failure: an uptodate 88
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 87
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 86
"ischemic" ST elevation in a woman with left ventricular hypertrophy 85
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 84
Redefining biomarkers in heart failure 84
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 84
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 81
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 80
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 80
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 79
COMPASS vs PEGASUS approach in a comparative budget impact analysis 79
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 78
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 77
New Targets in Heart Failure Drug Therapy 77
HIV-associated pulmonary arterial hypertension: from bedside to the future 76
Advanced heart failure: non-pharmacological approach 76
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 76
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 75
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 73
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 72
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 72
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 72
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 71
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 71
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 70
Delirium in heart failure 70
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 69
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 69
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 68
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 68
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 67
Effects of Sacubitril/Valsartan on the Renal Resistance Index 64
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 64
The thromboembolism in COVID-19: the unsolved problem 64
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 64
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 63
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 58
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 56
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 54
Flow Mediated Dilation in Systemic Sclerosis: Association with clinical findings, capillaroscopic patterns and endothelial circulating markers 52
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction 50
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets 47
Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function 47
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus 47
Impact of Frailty on Outcome of Older Patients With Non-ST Elevation Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention 46
Combined peripheral and central ultrasound for the diagnosis of PAH-SSc patients 45
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 45
Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension 45
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 45
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 45
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy 44
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 43
Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis 42
Left ventricular reverse remodeling after combined ARNI and SGLT2 therapy in heart failure patients with reduced or mildly reduced ejection fraction 42
Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach 42
Biomarker profiles that differentiate type-1 and type 2 myocardial infarction 42
Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside 42
The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction 41
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 41
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 41
Relationship between the strain measures of left atrial function and heart failure worsening 39
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 39
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 38
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 37
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 36
Endothelial Function Correlates With Pulmonary Pressures in Subjects With Clinically Suspected Pulmonary Hypertension 36
SGLT2 Inhibitors Introduction and Changes of the Other Disease Modifiers’ Drugs in Heart Failure Patients: A Single Center Real World Experience 36
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience 36
Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging 34
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 34
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 33
Acute coronary syndrome with single‑lead ST segment elevation: A rare presentation of multivessel coronary artery disease 33
Alcohol consumption and subclinical and clinical coronary heart disease: New insight into potential causal mechanisms 32
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest 32
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? 32
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 31
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 30
Totale 6.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.511
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.511
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021217 0 0 0 0 0 3 51 54 52 56 1 0
2021/2022412 17 2 11 3 70 14 11 38 49 86 6 105
2022/20231.331 117 69 83 38 31 104 2 86 702 10 40 49
2023/2024585 57 18 39 19 79 124 13 94 1 11 14 116
2024/20251.735 88 18 28 77 50 243 159 115 456 153 198 150
2025/20261.679 310 321 444 304 194 106 0 0 0 0 0 0
Totale 6.879